AMD drug reimbursement pressure rising in US
This article was originally published in Scrip
Executive Summary
European pricing and reimbursement pressure for anti-VEGF therapies that treat age-related macular degeneration (AMD) and diabetic macular edema (DME) has been well documented over the past several months, but similar pressure is building in the US where Eylea (aflibercept) and Lucentis (ranibizumab) are seen by retina specialists as the most effective treatment options.